PUBLISHER: DelveInsight | PRODUCT CODE: 1058079
PUBLISHER: DelveInsight | PRODUCT CODE: 1058079
DelveInsight's 'Chlamydia - Market Insights, Epidemiology, and Market Forecast - 2032' report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the market trends of chlamydia in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The Chlamydia market report provides current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted Chlamydia market Size from 2019 to 2032, segmented by seven major markets. The report also covers the current Chlamydia treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying market potential.
Chlamydial infection, caused by Chlamydia trachomatis, is the most common bacterial sexually transmitted infection (STI). Age is a strong predictor of risk for chlamydial infections, with the highest infection rates in women occurring during ages 15-24 years. As most individuals with the infection are asymptomatic, it is often left untreated, increasing the risk of transmission and serious health consequences in both sexes. If symptoms occur, they usually appear two to six weeks after infection. Symptoms can include vaginal pain and bleeding, painful urination, and an abnormal discharge from the vagina, urethra, or rectum.
Untreated infection can result in serious complications such as pelvic inflammatory disease, infertility, ectopic pregnancy in women, and epididymitis and orchitis in men. Maternal infection is associated with serious adverse outcomes in neonates, such as preterm birth, low birth weight, conjunctivitis, nasopharyngeal infection, and pneumonia. Screening for chlamydia is implemented in several countries and regions, including the US and the UK, to reduce the risks. Screening is recommended in all women younger than 25 years, in all pregnant women, and in women who are at increased risk of infection.
The Aptima Combo 2 Assay and the Xpert CT/NG were the first tests cleared for extragenital diagnostic testing to detect the presence of the bacteria Chlamydia trachomatis via the throat and rectum. These tests were previously only cleared for testing urine, vaginal and endocervical samples. The availability of these two tests helped fill an unmet public health need by allowing for more screening. Recently, US FDA approved using the Binx Health IO CT/NG Assay at point-of-care settings to help with more quick and appropriate treatment of chlamydia. Access to faster diagnostic results and proper treatments will make significant strides in combatting Chlamydia infections.
Treating C. trachomatis prevents adverse reproductive health complications and continued sexual transmission. Furthermore, treating the sex partners prevent reinfection and infection of other partners. Also, treating pregnant women usually prevents C. trachomatis in neonates during birth. For the treatment of chlamydia infection, the Centers for Disease Control and Prevention (CDC) recommends 100 mg of doxycycline twice daily for 7 days. Alternate regimens include oral administration of either 1 g of azithromycin in a single dose of Levofloxacin 500 mg orally once daily for 7 days.
While antibiotics have successfully treated most uncomplicated C. trachomatis urogenital infections, treatment does not generally resolve persistent infections or prevent autoimmunity. Repeat and persistent infections are common among at-risk adolescent and young adult populations. Even with appropriate detection, there is increasing evidence for antibiotic resistance to the common drugs used to treat C. trachomatis.
It covers the details of conventional and current medical therapies and diagnoses available in the Chlamydia market to treat the condition. It also provides the country-wise treatment guidelines and algorithms across the United States, Europe, and Japan.
The DelveInsight Chlamydia Market Report gives a thorough understanding of chlamydia by including details of disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides the treatment algorithms and treatment guidelines for Chlamydia in the US, Europe, and Japan.
The Chlamydia epidemiology division provides insights into the historical and current patient pool and the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed incident patient pool, trends, and assumptions.
The disease epidemiology covered in the report provides historical and forecasted Chlamydia epidemiology segmented as the diagnosed incident cases of chlamydia, gender-specific cases of chlamydia, symptom-specific cases of Chlamydia and age-specific cases of Chlamydia. The report includes the diagnosed incident scenario of Chlamydia symptoms in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.
The epidemiology segment also provides the Chlamydia epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
The diagnosed incident Chlamydia population in the 7MM countries was estimated to be 3,453,387 cases in 2021.
The drug chapter segment of the Chlamydia report encloses the detailed analysis of Chlamydia marketed drugs and late stage (Phase-III, Phase-II/III, Phase-II, and Phase-I/II) pipeline drugs. It also helps to understand the Chlamydia clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.
Recently, in 2021, CDC updated STI guidelines for the treatment of chlamydia to overcome resistance development. According to these updated guidelines, the recommended treatment of chlamydia is now doxycycline 100 mg twice daily orally for 7 days. Alternative regimens include either azithromycin 1 g orally in a single dose or levofloxacin 500 mg once daily for 7 days. Notably, there is a delayed-release (DR) formulation of doxycycline available on the market to lighten the pill burden for patients and ease gastrointestinal effects.
EVO100 (previously known as Amphora Gel) is an investigational vaginal gel to prevent urogenital chlamydia and gonorrhea in women. The drug is designed to reduce certain vaginal infections by balancing vaginal pH, thereby maintaining healthy vaginal flora and creating an environment that is detrimental to the growth and proliferation of harmful bacteria, using a different mechanism of action that may help to address drug resistance concerns
US FDA has granted the drug fast track designation for the prevention of chlamydia in women. The Phase IIb AMPREVENCE study evaluating EVO100 for the prevention of chlamydia and gonorrhea met its primary and secondary endpoints, and the study showed that EVO100 was generally safe and well-tolerated. The drug is currently being evaluated in pivotal Phase III urogenital chlamydia trachomatis and Neisseria gonorrhea infection in women. Top-line results are expected in 2022.
The Chlamydia market outlook of the report builds a detailed comprehension of the historical, current, and forecasted Chlamydia market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand for better technology.
This segment gives a thorough detail of the Chlamydia market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need for the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the Chlamydia market in the 7MM is expected to change in the study period 2019-2032.
Presently, unmet needs in treatment for chlamydia are significant, with around 30% of patients having chronic progressive disease, unresponsive to steroid treatment. Also, there is no clear-cut PAH-specific therapy with proven efficacy or approval for treating SAPH. Thus, there is an increased demand for disease-modifying therapies to cater to the needs of patients.
This section includes a glimpse of the Chlamydia market in the 7MM. The market size of chlamydia in the seven major markets was USD 59.5 million in 2021.
This section provides the total Chlamydia market size and market size by therapies of Chlamydia in the United States.
The United States accounts for the highest market size of chlamydia compared to the EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.
For many years, azithromycin has been considered the drug of choice for treating C. trachomatis infections.
The advent of azithromycin resistance is due to its extensive usage to treat infections. For chlamydia treatment, data obtained from azithromycin versus doxycycline studies show higher treatment failure rates with azithromycin compared to doxycycline.
According to recent CDC guidelines, the recommended treatment of chlamydia is now doxycycline 100 mg twice daily orally for 7 days.
Antimicrobial stewardship is a program that supports the proper use of antimicrobials to circumvent resistance, one of the major public health problems in the United States. The new updates have been recommended based on the concerns regarding increased rates of azithromycin resistance and ceftriaxone resistance when used at lower doses.
Alternative regimens include either azithromycin 1 g orally in a single dose or levofloxacin 500 mg once daily for 7 days. Also, Ofloxacin (but not all other quinolones) effectively treat chlamydial infections. In general, erythromycin is considered the backup drug for those who cannot take another regimen.
The total Chlamydia market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are also mentioned.
The total Chlamydia market size and market size by therapies of Chlamydia in Japan are also mentioned.
This section focuses on the rate of uptake of the potential drugs recently launched or expected to get launched in the market during the study period 2019-2032. The analysis covers Chlamydia market uptake by drugs, patient uptake by therapies, and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allow the comparison of the drugs based on market share and size, which again will be useful in investigating factors important in the market uptake and in making financial and regulatory decisions.
The report provides insights into different therapeutic candidates in Phase III, Phase II/III, Phase II, and Phase I/II stage. It also analyses chlamydia's key players involved in developing targeted therapeutics.
Major players include Evofem Biosciences, Abera Bioscience, Prokarium, Quretech Bio, Aeterna Zentaris, and others, whose key products are expected to get launched in the US market by 20XX.
The report covers the detailed information of collaborations, acquisition and merger, licensing, and patent details for Chlamydia emerging therapies.
To keep up with current market trends, we take KOLs and SMEs' opinions working in the Chlamydia domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Chlamydia market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.
We perform a Competitive and Market Intelligence analysis of the Chlamydia market using various Competitive Intelligence tools: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.